Nextcure Inc.(NXTC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NXTC Nextcure Inc.

盘前交易 08-14 06:02:04 EDT

8.28

+0.11

+1.35%

盘前8.25

-0.03-0.36%

05:29 EDT

最高8.66	最低7.83	成交量28.61万
今开8.24	昨收8.17	日振幅10.16%
总市值3,790万	流通市值2,072万	总股本457.74万
成交额236.91万	换手率11.43%	流通股本250.27万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NXTC","market":"US","secType":"STK","nameCN":"Nextcure Inc.","latestPrice":8.28,"timestamp":1786651200000,"preClose":8.17,"halted":0,"volume":286078,"hourTrading":{"tag":"盘前","latestPrice":8.25,"preClose":8.28,"latestTime":"05:29 EDT","volume":691,"amount":5695.1881410000005,"timestamp":1786699760268,"change":-0.03,"changeRate":-0.003623,"amplitude":0.034106},"delay":0,"changeRate":0.01346389228886162,"floatShares":2502700,"shares":4577400,"eps":-9.935501,"marketStatus":"盘前交易","change":0.11,"latestTime":"08-14 06:02:04 EDT","open":8.24,"high":8.66,"low":7.83,"amount":2369067.70321,"amplitude":0.101591,"askPrice":8.5,"askSize":500,"bidPrice":7.21,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.935501,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786714200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":8.28,"preHourTrading":{"tag":"盘前","latestPrice":8.25,"preClose":8.28,"latestTime":"05:29 EDT","volume":691,"amount":5695.1881410000005,"timestamp":1786699760268,"change":-0.03,"changeRate":-0.003623,"amplitude":0.034106},"postHourTrading":{"tag":"盘后","latestPrice":8.121,"preClose":8.28,"latestTime":"19:50 EDT","volume":2907,"amount":23700.7172,"timestamp":1786665049906,"change":-0.159,"changeRate":-0.019203,"amplitude":0.019324},"volumeRatio":0.5560062033482076,"impliedVol":0.7756,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/NXTC/tweets","defaultTab":"tweets","newsList":[{"id":"1148854158","title":"NextCure第二季度净亏损1490万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148854158","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148854158?lang=zh_cn&edition=full","pubTime":"2026-08-07 04:18","pubTimestamp":1786047528,"startTime":"0","endTime":"0","summary":"NextCure Inc. 最新发布的第二季度财报显示，该公司的净收入为负1490万美元。这一数字，在市场上投下了一道阴影。与此同时，其基本每股收益（EPS）为-2.8美元，反映出公司在这一时期的盈利状况十分严峻。\n这一财务结果，无疑揭示了NextCure在当前阶段的经营挑战。从数据上看，公司似乎在收入端面临不小的压力，导致净利润难以转正。每股收益的亏损数值，则进一步放大了投资者对该公司短期盈利能力的担忧。市场参与者或许会据此重新评估其投资价值，并密切关注其后续的研发管线进展与成本控制措施。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151148378","title":"翰森制药旗下Avere Therapeutics将依据2026年7月14日签署的合并协议并入Nextcure","url":"https://stock-news.laohu8.com/highlight/detail?id=1151148378","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151148378?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:02","pubTimestamp":1784023337,"startTime":"0","endTime":"0","summary":"翰森制药旗下子公司Avere Therapeutics，将依据2026年7月14日正式签署的合并协议，并入生物技术公司Nextcure Inc.。此次合并旨在整合双方在创新疗法领域的资源与专长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK4139","BK1589","BK1583","BK1191","NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109086481","title":"Nextcure与翰森制药达成协议：支付1.2亿美元首付款及最高21.8亿美元里程碑款项，外加AVR-1中国以外区域权利特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1109086481","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109086481?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:01","pubTimestamp":1784023292,"startTime":"0","endTime":"0","summary":"Nextcure公司宣布，已与翰森制药集团达成一项授权协议。根据协议条款，Nextcure将获得其候选药物AVR-1在中国以外地区的开发和商业化权利。\n为此，Nextcure需向翰森制药支付1.2亿美元的首付款。此外，协议还包含了高达21.8亿美元的潜在里程碑付款，具体金额取决于AVR-1在未来研发和商业化进程中取得的各项成就。在药物成功上市销售后，Nextcure还需根据净销售额向翰森制药支付分层特许权使用费。\nAVR-1是一种处于研究阶段的治疗性抗体，旨在针对特定的肿瘤靶点。此次交易旨在加速该疗法在全球市场（不包括中国）的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127728741","title":"Nextcure股东将在交易完成后两年内获得管线货币化净收益的90%作为CVR","url":"https://stock-news.laohu8.com/highlight/detail?id=1127728741","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127728741?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:01","pubTimestamp":1784023283,"startTime":"0","endTime":"0","summary":"Nextcure公司宣布，其股东将获得一项或有价值权利（CVR）。根据该权利，在交易完成后的两年内，股东有权获得公司管线资产货币化所产生净收益的90%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148150429","title":"Nextcure宣布可回看讨论Sim0505治疗妇科癌症1期试验ASCO 2026剂量递增数据的虚拟KOL活动","url":"https://stock-news.laohu8.com/highlight/detail?id=1148150429","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148150429?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:02","pubTimestamp":1780574547,"startTime":"0","endTime":"0","summary":"Nextcure公司宣布，一场讨论Sim0505治疗妇科癌症1期试验在2026年美国临床肿瘤学会年会上公布的剂量递增数据的虚拟关键意见领袖活动，现已提供回看。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150994657","title":"NextCure加速项目开发 将临床研究网络拓展至加拿大与欧洲","url":"https://stock-news.laohu8.com/highlight/detail?id=1150994657","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150994657?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:09","pubTimestamp":1777892964,"startTime":"0","endTime":"0","summary":"生物技术公司NextCure Inc.宣布，正通过将其临床研究中心网络扩展至加拿大和欧洲地区，加速其研发项目的推进步伐。这一战略布局将显著提升公司临床试验的全球覆盖能力，为后续药物开发提供更广阔的患者群体和更高效的研究数据收集渠道。跨国临床站点的建立不仅有助于加快研发进程，还能增强研究数据的多样性和代表性，为未来监管审批奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150730577","title":"NextCure与先声再明启动妇科癌症药物Sim0505（Cdh6 ADC）剂量优化研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1150730577","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150730577?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:07","pubTimestamp":1777892835,"startTime":"0","endTime":"0","summary":"NextCure与先声再明公司已正式启动针对Sim0505（一种靶向Cdh6的抗体偶联药物）在妇科癌症治疗中的剂量优化研究。这项重要进展标志着该创新疗法在临床开发道路上迈出了关键一步，旨在通过精确调整给药方案，为患者寻找最佳治疗窗口。\n此次剂量优化研究将系统评估不同给药策略下的安全性与有效性数据，为后续临床试验提供科学依据。双方科研团队将密切合作，加速推进这一具有潜力的肿瘤治疗药物的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618909523","title":"Nextcure, Inc.盘中异动 临近收盘急速拉升6.06%报13.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618909523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618909523?lang=zh_cn&edition=full","pubTime":"2026-03-12 03:58","pubTimestamp":1773259100,"startTime":"0","endTime":"0","summary":"北京时间2026年03月12日03时58分，Nextcure, Inc.股票出现异动，股价大幅上涨6.06%。截至发稿，该股报13.48美元/股，成交量4.3323万股，换手率1.24%，振幅7.08%。Nextcure, Inc.股票所在的生物技术行业中，整体跌幅为1.01%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段的生物制药公司，致力于发现和开发新型、一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312035820a461f3bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312035820a461f3bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456854461.SGD","CRC","LU0266512127.USD","NXTC","BK4213","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616350999","title":"Nextcure, Inc.股价重挫16.82% 市值跌41.52万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616350999","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616350999?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:38","pubTimestamp":1772462339,"startTime":"0","endTime":"0","summary":"北京时间2026年03月02日22时38分，Nextcure, Inc.股票出现异动，股价大幅下跌16.82%。截至发稿，该股报10.58美元/股，成交量1234股，换手率0.04%，振幅0.00%。Nextcure, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段的生物制药公司，致力于发现和开发新型、一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030222390097a7af0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030222390097a7af0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4213","BK4139","CRC","LU0266512127.USD","NXTC","LU0456854461.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518284977","title":"Nextcure, Inc.2024财年实现净利润-55.65百万美元，同比增加11.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518284977","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518284977?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:01","pubTimestamp":1741536082,"startTime":"0","endTime":"0","summary":"3月10日，Nextcure, Inc.公布财报，公告显示公司2024财年净利润为-55.65百万美元，同比增加11.27%；其中营业收入为0.00美元，每股基本收益为-1.99美元。从资产负债表来看，Nextcure, Inc.总负债16.45百万美元，其中短期债务796000.00美元，资产负债比为4.98，流动比率为7.51。机构评级：截至2025年3月10日，当前有2家机构对Nextcure, Inc.目标价做出预测，其中目标均价为3.00美元，其中最低目标价为3.00美元，最高目标价为3.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000304a2689894&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000304a2689894&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517145291","title":"NextCure(NXTC.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.41美元，前值为-0.52美元，预期值为-0.36美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517145291","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517145291?lang=zh_cn&edition=full","pubTime":"2025-03-07 06:57","pubTimestamp":1741301839,"startTime":"0","endTime":"0","summary":"NextCure(NXTC.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.41美元，前值为-0.52美元，预期值为-0.36美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07065748578832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113678994","title":"NextCure 2024财年GAAP每股收益$(1.99)不及预期$(1.92)","url":"https://stock-news.laohu8.com/highlight/detail?id=1113678994","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113678994?lang=zh_cn&edition=full","pubTime":"2025-03-07 05:19","pubTimestamp":1741295952,"startTime":"0","endTime":"0","summary":"NextCure（NASDAQ:NXTC）报告季度每股亏损$(1.99)，低于分析师一致预期$(1.92)，差幅为3.65%。以上内容来自Benzinga Earnings专栏，原文如下：NextCure (NASDAQ:NXTC) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(1.92) by 3.65 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NextCure 2024财年GAAP每股收益$(1.99)不及预期$(1.92)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517167564","title":"Nextcure, Inc.盘中异动 早盘大幅上涨5.41%报0.780美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517167564","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517167564?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:04","pubTimestamp":1741277091,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时04分，Nextcure, Inc.股票出现异动，股价快速上涨5.41%。截至发稿，该股报0.780美元/股，成交量2.2204万股，换手率0.08%，振幅4.36%。Nextcure, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段生物制药公司，致力于发现和开发新型，一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000451abeb8e07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000451abeb8e07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0456854461.SGD","CRC","LU0266512127.USD","NXTC","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517943623","title":"Nextcure, Inc.盘中异动 大幅拉升5.53%报0.780美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943623","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517943623?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:49","pubTimestamp":1741186149,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时49分，Nextcure, Inc.股票出现波动，股价急速上涨5.53%。截至发稿，该股报0.780美元/股，成交量770股，换手率0.00%，振幅0.00%。Nextcure, Inc.股票所在的生物技术行业中，整体涨幅为1.51%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段生物制药公司，致力于发现和开发新型，一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224909963ae0f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224909963ae0f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRC","LU0266512127.USD","BK4139","BK4213","NXTC","LU0456854461.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517067216","title":"Nextcure, Inc.盘中异动 快速下跌7.98%报0.671美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517067216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517067216?lang=zh_cn&edition=full","pubTime":"2025-03-05 00:09","pubTimestamp":1741104554,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日00时09分，Nextcure, Inc.股票出现波动，股价大幅下跌7.98%。截至发稿，该股报0.671美元/股，成交量1.0797万股，换手率0.04%，振幅5.49%。Nextcure, Inc.股票所在的生物技术行业中，整体跌幅为0.41%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段生物制药公司，致力于发现和开发新型，一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030500091496395e97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030500091496395e97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456854461.SGD","BK4213","BK4139","LU0266512127.USD","CRC","NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516668245","title":"Nextcure, Inc.盘中异动 下午盘股价大跌6.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668245","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516668245?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:31","pubTimestamp":1741030270,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时31分，Nextcure, Inc.股票出现异动，股价大幅下跌6.41%。截至发稿，该股报0.729美元/股，成交量6210股，换手率0.02%，振幅4.49%。Nextcure, Inc.股票所在的生物技术行业中，整体涨幅为0.55%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段生物制药公司，致力于发现和开发新型，一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304033111989a519e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304033111989a519e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456854461.SGD","BK4213","NXTC","LU0266512127.USD","BK4139","CRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514200733","title":"Nextcure, Inc.盘中异动 股价大跌8.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514200733","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514200733?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:33","pubTimestamp":1740753228,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时33分，Nextcure, Inc.股票出现异动，股价大幅下挫8.74%。Nextcure, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段生物制药公司，致力于发现和开发新型，一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223349963419e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223349963419e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRC","LU0456854461.SGD","NXTC","LU0266512127.USD","BK4139","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513472061","title":"Nextcure, Inc.盘中异动 早盘大幅拉升6.38%报0.769美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513472061","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513472061?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:00","pubTimestamp":1740409211,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时00分，Nextcure, Inc.股票出现波动，股价快速拉升6.38%。截至发稿，该股报0.769美元/股，成交量3473股，换手率0.01%，振幅0.00%。Nextcure, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段生物制药公司，致力于发现和开发新型，一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242300129890fcec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242300129890fcec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456854461.SGD","CRC","LU0266512127.USD","BK4139","BK4213","NXTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512486933","title":"Nextcure, Inc.盘中异动 早盘股价大涨6.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512486933","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512486933?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:50","pubTimestamp":1739976648,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时50分，Nextcure, Inc.股票出现异动，股价急速上涨6.43%。Nextcure, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段生物制药公司，致力于发现和开发新型，一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225048a24bfe41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225048a24bfe41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0266512127.USD","BK4213","NXTC","LU0456854461.SGD","CRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511469675","title":"Nextcure, Inc.盘中异动 早盘快速上涨5.84%报0.767美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511469675","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511469675?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:46","pubTimestamp":1739544364,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时46分，Nextcure, Inc.股票出现异动，股价大幅拉升5.84%。截至发稿，该股报0.767美元/股，成交量1490股，换手率0.01%，振幅3.51%。Nextcure, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Nextcure, Inc.公司简介：NextCure Inc 是一家临床阶段生物制药公司，致力于发现和开发新型，一流的免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224605abcf09d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224605abcf09d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRC","LU0266512127.USD","NXTC","BK4139","BK4213","LU0456854461.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nextcure.com","stockEarnings":[{"period":"1week","weight":0.4812},{"period":"1month","weight":0.2584},{"period":"3month","weight":-0.1499},{"period":"6month","weight":-0.3679},{"period":"1year","weight":0.5954},{"period":"ytd","weight":-0.4165}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"NextCure, Inc.于2015年9月在特拉华州注册成立，总部位于马里兰州贝尔茨维尔。 该公司是一家临床阶段的生物制药公司，致力于发现和开发新型的一流免疫药物，通过恢复正常的免疫功能来治疗癌症和其他免疫相关疾病。 通过其专有的功能性，集成式，免疫肿瘤学中的NextCure Discovery（“FIND-IO”）平台，公司研究各种免疫细胞，以发现和了解免疫细胞的靶标和结构成分及其功能影响，从而开发免疫组化。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.02663},{"month":2,"riseRate":0.285714,"avgChangeRate":0.046168},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.077039},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.142734},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.008819},{"month":6,"riseRate":0.5,"avgChangeRate":-0.126153},{"month":7,"riseRate":0.375,"avgChangeRate":0.140522},{"month":8,"riseRate":0.625,"avgChangeRate":0.176205},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.085295},{"month":10,"riseRate":0.428571,"avgChangeRate":0.136079},{"month":11,"riseRate":0.571429,"avgChangeRate":0.061609},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.021792}],"exchange":"NASDAQ","name":"Nextcure Inc.","nameEN":"Nextcure Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nextcure Inc.(NXTC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nextcure Inc.(NXTC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nextcure Inc.,NXTC,Nextcure Inc.股票,Nextcure Inc.股票老虎,Nextcure Inc.股票老虎国际,Nextcure Inc.行情,Nextcure Inc.股票行情,Nextcure Inc.股价,Nextcure Inc.股市,Nextcure Inc.股票价格,Nextcure Inc.股票交易,Nextcure Inc.股票购买,Nextcure Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nextcure Inc.(NXTC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nextcure Inc.(NXTC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}